Long-term Challenges After Solid Organ Transplantation: Summary of Expert Presentations From the Sandoz 5th Standalone Transplantation Meeting, 2017

[1]  E. Sáez-González,et al.  Impact of hepatitis C virus (HCV) antiviral treatment on the need for liver transplantation (LT) , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[2]  L. Potena,et al.  Clinical relevance of the International Society for Heart and Lung Transplantation consensus classification of primary graft dysfunction after heart transplantation: Epidemiology, risk factors, and outcomes. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  X. Jouven,et al.  Building a tissue-based molecular diagnostic system in heart transplant rejection: The heart Molecular Microscope Diagnostic (MMDx) System. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  A. Mittal,et al.  Skin Cancers in Organ Transplant Recipients , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  N. Heyne,et al.  Dynamics of Glucose Metabolism After Kidney Transplantation , 2017, Kidney and Blood Pressure Research.

[6]  G. Snell,et al.  Poor Glycemic Control Is Associated With Decreased Survival in Lung Transplant Recipients , 2017, Transplantation.

[7]  C. Nast,et al.  IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation , 2017, The New England journal of medicine.

[8]  G. Walters,et al.  Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients. , 2017, The Cochrane database of systematic reviews.

[9]  A. Åsberg,et al.  Associations Between Posttransplantation Diabetes Mellitus and Renal Graft Survival , 2017, Transplantation.

[10]  E. Huang,et al.  Association of Pretransplant Skin Cancer With Posttransplant Malignancy, Graft Failure and Death in Kidney Transplant Recipients , 2017, Transplantation.

[11]  R. Lechler,et al.  Strategies for long-term preservation of kidney graft function , 2017, The Lancet.

[12]  L. Rostaing,et al.  Reduction of Extended‐Release Tacrolimus Dose in Low‐Immunological‐Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor‐Specific Antibodies: A Randomized Study , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  B. Kasiske,et al.  Clinical and Economic Consequences of Early Cancer After Kidney Transplantation in Contemporary Practice , 2017, Transplantation.

[14]  A. Matas,et al.  Long‐Term Non–End‐Stage Renal Disease Risks After Living Kidney Donation , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  J. Neuberger,et al.  Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group , 2017, Transplantation.

[16]  Chengliang Zhang,et al.  Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials , 2017, PloS one.

[17]  A. Webster,et al.  Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients. , 2017, The Cochrane database of systematic reviews.

[18]  S. Kim,et al.  Cancer Screening Recommendations for Solid Organ Transplant Recipients: A Systematic Review of Clinical Practice Guidelines , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  B. Banas,et al.  Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial , 2016, The Lancet.

[20]  B. Sawitzki,et al.  Immune monitoring in renal transplantation: The search for biomarkers , 2016, European journal of immunology.

[21]  R. MacIsaac,et al.  A Prospective Study of Renal Transplant Recipients: A Fall in Insulin Secretion Underpins Dysglycemia After Renal Transplantation , 2016, Transplantation direct.

[22]  M. L. de la Mata,et al.  Controlling Diabetes After Liver Transplantation: Room for Improvement , 2016, Transplantation.

[23]  Yi Luan,et al.  Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study , 2016, The Lancet.

[24]  A. Sharif,et al.  Comparing glycaemic benefits of Active Versus passive lifestyle Intervention in kidney Allograft Recipients (CAVIAR): study protocol for a randomised controlled trial , 2016, Trials.

[25]  M. Stegall,et al.  Developing New Immunosuppression for the Next Generation of Transplant Recipients: The Path Forward , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  D. Cook,et al.  Palliative ICU beds for potential organ donors: an effective use of resources based on quality-adjusted life-years gained. , 2016, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[27]  D. Berg,et al.  Immunosuppressive Medications and Squamous Cell Skin Carcinoma: Nested Case‐Control Study Within the Skin Cancer after Organ Transplant (SCOT) Cohort , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  J. Larsen,et al.  Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes. , 2016, Endocrine reviews.

[29]  L. Rostaing,et al.  Belatacept and Long-Term Outcomes in Kidney Transplantation. , 2016, The New England journal of medicine.

[30]  A. Wallia,et al.  Hyperglycemia and Diabetes Mellitus Following Organ Transplantation , 2016, Current Diabetes Reports.

[31]  M. Crespo-Leiro,et al.  Twelve-month efficacy and safety of the conversion to everolimus in maintenance heart transplant recipients. , 2015, World journal of transplantation.

[32]  M. Kersten,et al.  Epstein-Barr Virus–Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management , 2015, Transplantation direct.

[33]  J. Stypmann,et al.  The MANDELA study: A multicenter, randomized, open-label, parallel group trial to refine the use of everolimus after heart transplantation. , 2015, Contemporary clinical trials.

[34]  N. Heyne,et al.  Diabetes Mellitus and Prediabetes on Kidney Transplant Waiting List- Prevalence, Metabolic Phenotyping and Risk Stratification Approach , 2015, PloS one.

[35]  J. Lai,et al.  Kidney Failure and Liver Allocation: Current Practices and Potential Improvements. , 2015, Advances in chronic kidney disease.

[36]  F. Fallani,et al.  Interplay of coronary angiography and intravascular ultrasound in predicting long-term outcomes after heart transplantation. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[37]  A. Israni,et al.  A prospective controlled study of living kidney donors: three-year follow-up. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[38]  N. De Maria,et al.  Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients , 2015, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[39]  J. Bradley,et al.  Early Graft Loss After Kidney Transplantation: Risk Factors and Consequences , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[40]  Amit X Garg,et al.  Living kidney donation: outcomes, ethics, and uncertainty , 2015, The Lancet.

[41]  P. Nickerson,et al.  Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients. , 2015, Journal of the American Society of Nephrology : JASN.

[42]  Yan Cui,et al.  New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy , 2015, Journal of Immunotherapy for Cancer.

[43]  L. P. Van den Heuvel,et al.  The functional implications of common genetic variation in CYP3A5 and ABCB1 in human proximal tubule cells. , 2015, Molecular pharmaceutics.

[44]  A. Garg,et al.  Gestational hypertension and preeclampsia in living kidney donors. , 2015, The New England journal of medicine.

[45]  G. McCaughan,et al.  Is there such a thing as protocol immunosuppression in liver transplantation? , 2015, Expert review of gastroenterology & hepatology.

[46]  G. Pacini,et al.  Proceedings From an International Consensus Meeting on Posttransplantation Diabetes Mellitus: Recommendations and Future Directions , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[47]  T. Therneau,et al.  Chronic kidney disease and associated mortality after liver transplantation--a time-dependent analysis using measured glomerular filtration rate. , 2014, Journal of hepatology.

[48]  F. Dekker,et al.  Long-term risks for kidney donors. , 2014, Kidney international.

[49]  C. Brander,et al.  HCV-Induced Immune Responses Influence the Development of Operational Tolerance After Liver Transplantation in Humans , 2014, Science Translational Medicine.

[50]  G. Gregoraci,et al.  Steroid-free and steroid withdrawal protocols in heart transplantation: the review of literature , 2014, Transplant international : official journal of the European Society for Organ Transplantation.

[51]  G. Klintmalm,et al.  The Role of Donor‐Specific HLA Alloantibodies in Liver Transplantation , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[52]  J. Gralla,et al.  Steroid Avoidance in Pediatric Heart Transplantation Results in Excellent Graft Survival , 2014, Transplantation.

[53]  Mei-Cheng Wang,et al.  Risk of end-stage renal disease following live kidney donation. , 2014, JAMA.

[54]  K. Wikenheiser-Brokamp,et al.  p53 suppresses carcinoma progression by inhibiting mTOR pathway activation , 2014, Oncogene.

[55]  V. Paradis,et al.  Assessment of chronic rejection in liver graft recipients receiving immunosuppression with low-dose calcineurin inhibitors. , 2013, Journal of hepatology.

[56]  D. Roelen,et al.  Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients , 2013, Hepatology.

[57]  R. Starling,et al.  Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial. , 2013, JACC. Heart failure.

[58]  H. Jörnvall,et al.  A meta-analysis of expression signatures in glomerular disease. , 2013, Kidney international.

[59]  B. Sangro,et al.  Trial of complete weaning from immunosuppression for liver transplant recipients: Factors predictive of tolerance , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[60]  A. Tura,et al.  Glucose Metabolism After Renal Transplantation , 2013, Diabetes Care.

[61]  C. Sánchez-Montes,et al.  Long‐term outcome of ‘long‐term liver transplant survivors’ , 2013, Transplant international : official journal of the European Society for Organ Transplantation.

[62]  I. Kerridge,et al.  Intimacy or utility? Organ donation and the choice between palliation and ventilation , 2013, Critical Care.

[63]  J. Neuberger,et al.  Late Acute Liver Allograft Rejection; A Study of Its Natural History and Graft Survival in the Current Era , 2013, Transplantation.

[64]  J. Preiksaitis,et al.  Epstein‐Barr Virus and Posttransplant Lymphoproliferative Disorder in Solid Organ Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[65]  P. Chin-Hong,et al.  Human Papillomavirus in Solid Organ Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[66]  N. Kamar,et al.  Complement Genes Strongly Predict Recurrence and Graft Outcome in Adult Renal Transplant Recipients with Atypical Hemolytic and Uremic Syndrome , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[67]  S. Messinger,et al.  Inhibitors of mTOR and Risks of Allograft Failure and Mortality in Kidney Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[68]  L. Ratner,et al.  Donor-specific antibodies adversely affect kidney allograft outcomes. , 2012, Journal of the American Society of Nephrology : JASN.

[69]  A. Castro‐Beiras,et al.  Percutaneous coronary interventions and bypass surgery in patients with cardiac allograft vasculopathy: a single-center experience. , 2012, Transplantation proceedings.

[70]  W. Chapman,et al.  Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[71]  A. Qureshi,et al.  Spouses Who Donate Seem to Be the Winners – A Questionnaire Study of Kidney Donors Long-Term , 2012 .

[72]  A. Burroughs,et al.  Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). , 2012, Journal of hepatology.

[73]  K. Rufibach,et al.  Statins and the Risk of Cancer After Heart Transplantation , 2012, Circulation.

[74]  A. Goldfarb-Rumyantzev,et al.  Access to renal transplantation in the diabetic population–effect of comorbidities and body mass index , 2012, Clinical transplantation.

[75]  A. Tura,et al.  Early basal insulin therapy decreases new-onset diabetes after renal transplantation. , 2012, Journal of the American Society of Nephrology : JASN.

[76]  C. Kubal,et al.  Chronic Kidney Disease After Nonrenal Solid Organ Transplantation: A Histological Assessment and Utility of Chronic Allograft Damage Index Scoring , 2012, Transplantation.

[77]  A. Matas,et al.  Understanding the Causes of Kidney Transplant Failure: The Dominant Role of Antibody‐Mediated Rejection and Nonadherence , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[78]  P. Rosenthal,et al.  Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. , 2012, JAMA.

[79]  A. Israni,et al.  Spectrum of cancer risk among US solid organ transplant recipients. , 2011, JAMA.

[80]  J. Neuberger,et al.  Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: Time to reconsider immunosuppression regimens? , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[81]  Josef Stehlik,et al.  The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report--2011. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[82]  F. Schena,et al.  Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial , 2011, Transplantation.

[83]  N. Kvarnström,et al.  Post-nephrectomy development of renal function in living kidney donors: a cross-sectional retrospective study. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[84]  S. Pham,et al.  New onset diabetes after transplantation (NODAT): an overview , 2011, Diabetes, metabolic syndrome and obesity : targets and therapy.

[85]  Thomas Becker,et al.  Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial , 2011, The Lancet.

[86]  M. Camacho,et al.  A Prospective, Randomized Trial of Single-Drug Versus Dual-Drug Immunosuppression in Heart TransplantationClinical Perspective , 2011 .

[87]  G. Tisone,et al.  Characterization of γδ T cell subsets in organ transplantation , 2010, Transplant international : official journal of the European Society for Organ Transplantation.

[88]  F. Lehner,et al.  Biopsy‐Diagnosed Renal Disease in Patients After Transplantation of Other Organs and Tissues , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[89]  W. Kremers,et al.  Evolution of Causes and Risk Factors for Mortality Post‐Liver Transplant: Results of the NIDDK Long‐Term Follow‐Up Study , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[90]  Jeff Reeve,et al.  A molecular classifier for predicting future graft loss in late kidney transplant biopsies. , 2010, The Journal of clinical investigation.

[91]  R. Marcus,et al.  Management of post‐transplant lymphoproliferative disorder in adult solid organ transplant recipients – BCSH and BTS Guidelines , 2010, British journal of haematology.

[92]  A. Webster,et al.  Long-term cancer risk of immunosuppressive regimens after kidney transplantation. , 2010, Journal of the American Society of Nephrology : JASN.

[93]  A. Serra,et al.  Swiss clinical practice guidelines for skin cancer in organ transplant recipients. , 2010, Swiss medical weekly.

[94]  T. Schiano,et al.  The Variable Pathology of Kidney Disease After Liver Transplantation , 2010, Transplantation.

[95]  M. Stegall,et al.  Identifying Specific Causes of Kidney Allograft Loss , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[96]  B. Einollahi,et al.  Outcome of kidney transplantation in type 1 and type 2 diabetic patients and recipients with posttransplant diabetes mellitus. , 2008, Urology journal.

[97]  P. Parrilla,et al.  FoxP3 in Peripheral Blood Is Associated With Operational Tolerance in Liver Transplant Patients During Immunosuppression Withdrawal , 2008, Transplantation.

[98]  Jean Kanitakis,et al.  Skin Cancer in Organ Transplant Recipients—Where Do We Stand Today? , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[99]  V. Seyfert-Margolis,et al.  Marking a path to transplant tolerance. , 2008, The Journal of clinical investigation.

[100]  G. Klintmalm,et al.  SPARE-THE-NEPHRON (STN) TRIAL IN LIVER TRANSPLANT RECIPIENTS: INTERIM EFFICACY AND SAFETY OF MYCOPHENOLATE MOFETIL (MMF)/SIROLIMUS (SRL) MAINTENANCE THERAPY AFTER CNI WITHDRAWAL: 276 , 2008 .

[101]  J. Gill,et al.  Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[102]  Richard D Moore,et al.  Influence of Lifestyle Modification in Renal Transplant Recipients With Postprandial Hyperglycemia , 2008, Transplantation.

[103]  P. Halloran,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.

[104]  C. Parkinson,et al.  Management of solid tumours in organ-transplant recipients. , 2007, The Lancet. Oncology.

[105]  N. Assy,et al.  Randomized Controlled Trial of Total Immunosuppression Withdrawal in Liver Transplant Recipients: Role of Ursodeoxycholic Acid , 2007, Transplantation.

[106]  A. Webster,et al.  Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. , 2006, The Cochrane database of systematic reviews.

[107]  G. Tisone,et al.  Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. , 2006, Journal of hepatology.

[108]  Stephanie L. Nay,et al.  Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. , 2005, The Journal of investigative dermatology.

[109]  J. Schold,et al.  Sirolimus in Combination with Tacrolimus Is Associated with Worse Renal Allograft Survival Compared to Mycophenolate Mofetil Combined with Tacrolimus , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[110]  M. Mehra,et al.  It is time to stop ignoring malignancy in heart transplantation: a call to arms. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[111]  N. Heaton,et al.  Long-term outcome of immunosuppression withdrawal after liver transplantation. , 2005, Transplantation proceedings.

[112]  J. Moon,et al.  The Role of Donor Bone Marrow Infusions in Withdrawal of Immunosuppression in Adult Liver Allotransplantation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[113]  G. Loss,et al.  Tolerance: Is It Worth the Risk? , 2005, Transplantation.

[114]  R. Balshaw,et al.  New Onset Diabetes Mellitus in Patients Receiving Calcineurin Inhibitors: A Systematic Review and Meta‐Analysis , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[115]  G. Opelz,et al.  Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study Report , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[116]  J. Chapman,et al.  The natural history of chronic allograft nephropathy. , 2003, The New England journal of medicine.

[117]  J. Yélamos,et al.  Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression1 , 2003, Transplantation.

[118]  Bertram L Kasiske,et al.  Diabetes Mellitus after Kidney Transplantation in the United States , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[119]  D. Dunn,et al.  Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. , 2002, Kidney international.

[120]  S. Uemoto,et al.  WEANING OF IMMUNOSUPPRESSION IN LIVING DONOR LIVER TRANSPLANT RECIPIENTS1 , 2001, Transplantation.

[121]  R. Wolfe,et al.  Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. , 2001, Journal of the American Society of Nephrology : JASN.

[122]  F. Cosio,et al.  Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. , 2001, Kidney international.

[123]  J. Robertson.  The dead donor rule. , 1999, The Hastings Center report.

[124]  B. Portmann,et al.  Defining the outcome of immunosuppression withdrawal after liver transplantation , 1998, Hepatology.

[125]  M. Stenbeck,et al.  Kidney donors live longer. , 1997, Transplantation.

[126]  T. Starzl,et al.  Risks and benefits of weaning immunosuppression in liver transplant recipients: long-term follow-up. , 1997, Transplantation proceedings.

[127]  A. S. Wiener,et al.  Transplantation , 1963 .

[128]  L. Lund,et al.  The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report-2017; Focus Theme: Allograft ischemic time. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[129]  D. Samuel,et al.  International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT RECIPIENTS. , 2017, Transplantation.

[130]  K. Famulski,et al.  Antibody-mediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies. , 2014, Kidney international.

[131]  I. Fehrman‐Ekholm.  View from a living donor. , 2013, Clinical transplants.

[132]  N. Kemmer,et al.  Nonalcoholic Fatty Liver Disease Epidemic and Its Implications for Liver Transplantation. , 2013, Transplantation.

[133]  J. Craig,et al.  Cancer Screening in People Who Have Chronic Disease: The Example of Kidney Disease , 2011, Seminars in dialysis.

[134]  L. Mjörnstedt,et al.  Long-term Outcomes of Kidney Function in Living Kidney Donors – The Gothenburgh Experience , 2010 .

[135]  European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.10. Pregnancy in renal transplant recipients. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.